Reuters logo
6 months ago
BRIEF-Amicus Therapeutics reiterates full-year 2017 financial guidance
March 1, 2017 / 12:14 PM / 6 months ago

BRIEF-Amicus Therapeutics reiterates full-year 2017 financial guidance

March 1 (Reuters) - Amicus Therapeutics Inc:

* Amicus Therapeutics announces full-year 2016 financial results and corporate updates

* Amicus Therapeutics Inc- target enrollment achieved in phase 1/2 pompe study, additional data expected in 2q17 and 3q17

* Amicus Therapeutics Inc- phase 3 EB program remains on track for topline data in mid-2017

* Amicus Therapeutics Inc- reiterated full-year 2017 financial guidance

* Amicus Therapeutics Inc- cash, cash equivalents, and marketable securities totaled $330.4 million at December 31, 2016

* Amicus Therapeutics Inc - company expects full-year 2017 net operating cash spend of between $175 million to $200 million

* Amicus Therapeutics Inc - expects full-year 2017 total net cash spend of between $200 million and $225 million

* Amicus Therapeutics Inc - current cash position is anticipated to fund ongoing operations into second half of 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below